Please provide your email address to receive an email when new articles are posted on . The receptor for advanced glycation end-products (RAGE) regulates pathways that contribute to inflammation.

Arrowhead Pharma doses first subjects in phase 1/2a study of ARO-MAPT to treat Alzheimer’s disease and other tauopathies: Pasadena, California Thursday, December 11, 2025, 12:00 ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD platform. Zerlasiran, the company’s main ...

- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to ...